Recombinant Human CD48 Protein (mFc Tag) | PKSH033522

Recombinant Human CD48 Protein (mFc Tag) | PKSH033522 | Gentaur US, UK & Europe Disrtribition

Synonyms: CD48 antigen; B-lymphocyte activation marker BLAST-1; BCM1 surface antigen; Leukocyte antigen MEM-102; TCT.1; CD48; BCM1;BLAST1;hCD48;mCD48;SLAMF2

Active Protein: N/A

Activity: Recombinant Human SLAM Family Member 2 is produced by our Mammalian expression system and the target gene encoding Gln27-Ser220 is expressed with a mFc tag at the C-terminus.

Protein Construction: Recombinant Human SLAM Family Member 2 is produced by our Mammalian expression system and the target gene encoding Gln27-Ser220 is expressed with a mFc tag at the C-terminus.

Fusion Tag: C-mFc

Species: Human

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per μg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 48.9 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of 20 mM Tris, 150mM NaCl, pH8.0.

Reconstitution: Please refer to the printed manual for detailed information.

Background: CD48 antigen; also known as B-lymphocyte activation marker BLAST-1; BCM1 surface antigen; Leukocyte antigen MEM-102; TCT.1; CD48; BCM1;and BLAST1; CD48 contains one Ig-like C2-type domain and one Ig-like V-type domain; but does not have a transmembrane domain; however; but is held at the cell surface by a GPI anchor via a C-terminal domain which maybe cleaved to yield a soluble form of the receptor. CD48 may facilitate interaction between activated lymphocytes and be involved in regulating T-cell activation. CD48 plays a vital role as an environmental sensor for regulating progenitor cell numbers and inhibiting tumor development. It is suggested that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against multiple myeloma.

Research Area: immunology